Boston Common Asset Management LLC Has $5.99 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Boston Common Asset Management LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 61.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 86,187 shares of the company's stock after acquiring an additional 32,927 shares during the period. Boston Common Asset Management LLC's holdings in Novo Nordisk A/S were worth $5,985,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in NVO. Center for Financial Planning Inc. grew its holdings in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares during the period. Strategic Investment Solutions Inc. IL grew its holdings in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares during the period. Park Square Financial Group LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $29,000. Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $33,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $39,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 2.8%

Shares of Novo Nordisk A/S stock traded up $1.94 during trading hours on Friday, reaching $71.40. 11,185,051 shares of the company's stock were exchanged, compared to its average volume of 6,800,832. The company has a 50 day moving average of $65.58 and a two-hundred day moving average of $81.59. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market cap of $320.41 billion, a P/E ratio of 21.70, a P/E/G ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion during the quarter. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on NVO shares. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Finally, BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $128.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.